Diamyd Medical

The Board of Directors in Diamyd Medical resolved on May 24, 2023, pursuant to the authorization granted by the annual general meeting in the Company on December 1, 2022, a rights issue of up to approximately SEK 163 million.

Preliminary outcome
The preliminary outcome indicates that approximately 8.4 million B-shares, corresponding to approximately 43 percent of the offered shares, have been subscribed for with subscription rights in the Rights Issue. Additionally, applications for subscription of approximately 0.5 million B-shares without subscription rights, corresponding to approximately 3 percent of the offered shares, have been received. Thus, the preliminary outcome indicates that the Rights Issue have been subscribed with the support of subscription rights and subscription applications without the support of subscription rights to approximately 46 percent. Through the Rights Issue, the Company will therefore receive approximately SEK 75 million before deduction of costs attributable to the Rights Issue.

Notice of allotment
All those who have subscribed for B-shares without subscription rights will be allocated B-shares in accordance with the principles set out in the EU growth prospectus which was approved and registered by the Swedish Financial Supervisory Authority on June 1, 2023. Notice of allotment to the persons who subscribed for B-shares without subscription rights is expected to be distributed on June 28, 2023. Subscribed and allotted B-shares shall be paid in cash within three banking days in accordance with the instructions on the settlement note sent to the subscriber. Subscribers who have subscribed for shares through a nominee will receive notification of allocation in accordance with their respective nominee's procedures. Only those who have been allotted shares will be notified.

Final outcome and trading in BTA's
The final outcome of the Rights Issue is expected to be published around June 28, 2023. The last day of trading in paid subscribed shares (Sw. BTA) is expected to be July 11, 2023. The new B-shares subscribed for with and without subscription rights are expected to be traded on Nasdaq First North Premier Growth Market as of week 29, 2023.

Advisors
G&W Fondkommission acts as Financial Advisor to Diamyd Medical in connection with the Rights Issue. Aqurat Fondkommission AB has been appointed as Issuer Agent.

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

About Diamyd Medical
Diamyd Medical develops precision medicine therapies for type 1 diabetes. Diamyd^® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. DIAGNODE-3, a confirmatory Phase 3 trial is actively recruiting patients with recent-onset type 1 diabetes in eight European countries and is being prepared to start recruiting patients in the US this summer. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company's European Phase 2b trial DIAGNODE-2, where the Diamyd^® was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. A biomanufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen^® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.